# EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

> **NCT01251926** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** EZN-2208
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01251926
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-15
- **Primary completion:** —
- **Final completion:** 2014-04-23
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251926, "EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01251926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*